INSPIRE: A randomized phase III trial of intravenous rigosertib in patients with higher-risk myelodysplastic syndromes (HR-MDS) after failure of hypomethylating agents (HMAs)—Study design informed by subgroup analyses of ONTIME
Garcia-Manero, Guillermo, Al-Kali, Aref, Baer, Maria R., Roboz, Gail J., Platzbecker, Uwe, Kambhampati, Suman, Godley, Lucy A., Collins, Robert, Shammo, Jamile M., Santini, Valeria, Raza, Dr. Azra, Silverman, Lewis R., Azarnia, Nozar, Fruchtman, Steven M., Snyder, Barbara R, Fenaux, Pierre
Published in Journal of clinical oncology (20.05.2016)
Published in Journal of clinical oncology (20.05.2016)
Get full text
Journal Article